Mov­ing to the em­ploy­er side of health­care, Mark Cuban's Cost Plus Drugs part­ners with a PBM

From “Shark Tank” to di­rect-to-con­sumer gener­ic drugs, Mark Cuban has made an­oth­er in­road in the on­go­ing bat­tle over pre­scrip­tion drug prices. His cost-plus-15% gener­ic drug com­pa­ny, fre­quent­ly un­der­cut­ting many com­peti­tors, now has its sights set on the em­ploy­er health­care mar­ket.

Cost Plus Drugs, which orig­i­nal­ly pledged to cut out PBMs, has now part­nered with the PBM Em­sa­naRx, ma­jor­i­ty owned by the Pur­chas­er Busi­ness Group on Health, to launch a sup­ple­men­tal drug dis­count pro­gram de­signed specif­i­cal­ly for self-fund­ed em­ploy­ers, the com­pa­ny an­nounced Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER